Archive for category: Latest Articles

Objectives

To evaluate the incidence and predictors of hospital readmission and emergency department (ED) visits in patients with benign prostatic hyperplasia treated by transurethral resection of the prostate (TURP).

Patients and Methods

We conducted a retrospective cohort study using a linked administrative dataset from Calgary, Canada. Participants were men who underwent their first TURP procedure between 2015 and 2017. We examined patient demographics, and type of surgery (elective or urgent). Comorbidities were scored using the Charlson comorbidity index (CCI). The primary outcomes were unplanned hospital readmissions and ED visits at 30, 60 and 90 days after TURP. The secondary aim was to identify potential predictors across these groups.

Results

We identified 3059 men, most of whom underwent elective TURP (83%). The mean (sd) patient age was 71.0 (10.0) years. A total of 224 patients (7.4%) were readmitted to the hospital within 30 days, 290 (9.5%) within 60 days, and 339 (11.1%) within 90 days of discharge. The frequency of return visits within 30, 60 and 90 days of TURP were 21.4%, 26% and 28.6%, respectively. The most responsible diagnoses for ED visit within 90 days were haematuria (15.4%) and retention of urine (12.8%). Multivariable analysis showed that age (odds ratio [OR] 1.61, P < 0.001), surgery type (OR 2.20, P < 0.001), and CCI score (OR 2.03, P < 0.001) were independently associated with odds of readmission and ED visits at all time points.

Conclusion

Older age, poorer health and urgent surgery predicted return to ED or readmission after TURP; efforts should be made to improve selection, counselling and preoperative optimization based on these risks.

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.